Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs (Q35683433)

9 August 2017

1 reference

title

Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs (English)

1 reference

9 August 2017

Cheng Luo

1 reference

9 August 2017

Pauliina Laaja

series ordinal

1 reference

9 August 2017

publication date

1 March 2004

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

9 August 2017

page(s)

268-275

1 reference

Interferon-induced nuclear signalling by Jak protein tyrosine kinases

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Cytokine signaling in 2002: new surprises in the Jak/Stat pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Series introduction. JAK-STAT signaling in human disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

A reinterpretation of the dimerization interface of the N-terminal domains of STATs

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Signaling through the JAK/STAT pathway, recent advances and future challenges

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Glycolipid-enriched membrane domains are assembled into membrane patches by associating with the actin cytoskeleton

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

The first seven amino acids encoded by the v-src oncogene act as a myristylation signal: lysine 7 is a critical determinant

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

The two faces of IL-6 on Th1/Th2 differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

The tumor suppressor activity of SOCS-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Regulation of JAK-STAT signalling in the immune system

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Enhanced Th2 cell-mediated allergic inflammation in Tyk2-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Constitutive activation of JAK1 in Src-transformed cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Stat proteins and oncogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Constitutively Activated Jak-STAT Pathway in T Cells Transformed with HTLV-I

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Stat3 activation by Src induces specific gene regulation and is required for cell transformation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

JAK-STAT signaling in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Cellular distribution and contribution of cyclooxygenase COX-2 to diabetogenesis in NOD mouse.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

INHIBITORS OF Src-FAMILY TYROSINE KINASES FAVOUR Th2 DIFFERENTIATION

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Regulation of Lck activity by CD4 and CD28 in the immunological synapse

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Effect of anti-IL-2Ralpha antibody on IL-2-induced Jak/STAT signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

What's in the pipeline? New immunosuppressive drugs in transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Integration of virtual and high-throughput screening

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Designing small-molecule switches for protein-protein interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Characterization of the in vitro kinase activity of a partially purified soluble GST/JAK2 fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Chronic myeloid leukemia in the imatinib era.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Structure-based design of novel anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Role of the JAK-STAT pathway in PDGF-stimulated proliferation of human airway smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

High-throughput crystallography for lead discovery in drug design.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Applications of one-bead one-compound combinatorial libraries and chemical microarrays in signal transduction research

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Mechanism-based design of a protein kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

The pp60c-Src inhibitor PP1 is non-competitive against ATP.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Signal Transduction: An Exciting Field of Investigation for Small Molecule Drug Discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Naphthyl ketones: a new class of Janus kinase 3 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Do structurally similar molecules have similar biological activity?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

The design, synthesis and activity of non-ATP competitive inhibitors of pp60(c-src) tyrosine kinase. Part 2: hydroxyindole derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903014-9

7 January 2021

10.1016/S1359-6446(03)03014-9

Identifiers

DOI

1 reference

9 August 2017

1 reference